Mediating Metabolism: Inhibition of Malic Enzyme 1 (ME1) Restores Endothelial Bioenergetics and Adenosine Signaling in Pulmonary Hypertension

HomeCirculationVol. 149, No. 17Mediating Metabolism: Inhibition of Malic Enzyme 1 (ME1) Restores Endothelial Bioenergetics and Adenosine Signaling in Pulmonary Hypertension No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextMediating Metabolism: Inhibition of Malic Enzyme 1 (ME1) Restores Endothelial Bioenergetics and Adenosine Signaling in Pulmonary Hypertension Rashmi J. Rao and Stephen Y. Chan Rashmi J. RaoRashmi J. Rao https://orcid.org/0000-0002-0429-0039 Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, PA. and Stephen Y. ChanStephen Y. Chan Correspondence to: Stephen Y. Chan, MD, PhD, Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, Division of Cardiology, University of Pittsburgh School of Medicine and UPMC, 200 Lothrop St, BST E1240, Pittsburgh, PA 15261. Email E-mail Address: [email protected] https://orcid.org/0000-0002-9520-7527 Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, Division of Cardiology, Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, PA. Originally published22 Apr 2024https://doi.org/10.1161/CIRCULATIONAHA.124.068738Circulation. 2024;149:1372–1374This article is a commentary on the followingInactivation of Malic Enzyme 1 in Endothelial Cells Alleviates Pulmonary HypertensionFootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Disclosures, see page 1374.Circulation is available at www.ahajournals.org/journal/circCorrespondence to: Stephen Y. Chan, MD, PhD, Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, Division of Cardiology, University of Pittsburgh School of Medicine and UPMC, 200 Lothrop St, BST E1240, Pittsburgh, PA 15261. Email chansy@pitt.eduREFERENCES1. Sakao S, Tatsumi K, Voelkel NF. Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation.Respir Res. 2009; 10:95. doi: 10.1186/1465-9921-10-95CrossrefMedlineGoogle Scholar2. Frump AL, Lahm T. The basic science of metabolism in pulmonary arterial hypertension.Adv Pulm Hypertens. 2018; 17:95–102. doi: 10.21693/1933-088x-17.3.95CrossrefGoogle Scholar3. Luo Y, Qi X, Zhang Z, Zhang J, Li B, Shu T, Li X, Hu H, Li J, Tang Q, et al. Inactivation of malic enzyme 1 in endothelial cells alleviates pulmonary hypertension.Circulation. 2024; 149:1354–1371. doi: 10.1161/CIRCULATIONAHA.123.067579LinkGoogle Scholar4. Piao L, Fang YH, Parikh K, Ryan JJ, Toth PT, Archer SL. Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension.J Mol Med (Berl). 2013; 91:1185–1197. doi: 10.1007/s00109-013-1064-7CrossrefMedlineGoogle Scholar5. Bertero T, Oldham WM, Cottrill KA, Pisano S, Vanderpool RR, Yu Q, Zhao J, Tai Y, Tang Y, Zhang Y-Y, et al. Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension.J Clin Invest. 2016; 126:3313–3335. doi: 10.1172/JCI86387CrossrefMedlineGoogle Scholar6. Yu Q, Tai YY, Tang Y, Zhao J, Negi V, Culley MK, Pilli J, Sun W, Brugger K, Mayr J, et al. BOLA (BolA family member 3) deficiency controls endothelial metabolism and glycine homeostasis in pulmonary hypertension.Circulation. 2019; 139:2238–2255. doi: 10.1161/CIRCULATIONAHA.118.035889LinkGoogle Scholar7. Diebold I, Hennigs JK, Miyagawa K, Li CG, Nickel NP, Kaschwich M, Cao A, Wang L, Reddy S, Chen P-I, et al. BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension.Cell Metab. 2015; 21:596–608. doi: 10.1016/j.cmet.2015.03.010CrossrefMedlineGoogle Scholar8. Culley MK, Chan SY. Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains.J Clin Invest. 2018; 128:3704–3715. doi: 10.1172/JCI120847CrossrefMedlineGoogle Scholar9. Culley MK, Zhao J, Tai YY, Tang Y, Perk D, Negi V, Yu Q, Woodcock CC, Handen A, Speyer G, et al. Frataxin deficiency promotes endothelial senescence in pulmonary hypertension.J Clin Invest. 2021; 131:e136459. doi: 10.1172/JCI136459CrossrefMedlineGoogle Scholar10. Harvey L, Chan S. Emerging metabolic therapies in pulmonary arterial hypertension.J Clin Med. 2017; 6:43. doi: 10.3390/jcm6040043CrossrefMedlineGoogle Scholar11. Wertheim BM, Wang R-S, Guillermier C, Hütter CVR, Oldham WM, Menche J, Steinhauser ML, Maron BA. Proline and glucose metabolic reprogramming supports vascular endothelial and medial biomass in pulmonary arterial hypertension.JCI Insight. 2023; 8:e163932. doi: 10.1172/jci.insight.163932CrossrefMedlineGoogle Scholar12. Alencar AKN, Montes GC, Barreiro EJ, Sudo RT, Zapata-Sudo G. Adenosine receptors as drug targets for treatment of pulmonary arterial hypertension.Front Pharmacol. 2017; 8:858. doi: 10.3389/fphar.2017.00858CrossrefMedlineGoogle Scholar13. Guieu R, Deharo J-C, Maille B, Crotti L, Torresani E, Brignole M, Parati G. Adenosine and the cardiovascular system: the good and the bad.J Clin Med. 2020; 9:1366. doi: 10.3390/jcm9051366CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesInactivation of Malic Enzyme 1 in Endothelial Cells Alleviates Pulmonary HypertensionYa Luo, et al. Circulation. 2024;149:1354-1371 April 23, 2024Vol 149, Issue 17 Advertisement Article InformationMetrics © 2024 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.124.068738PMID: 38648276 Originally publishedApril 22, 2024 KeywordsEditorialsadenosineenergy metabolismhypertension, pulmonarymalate dehydrogenase (decarboxylating)PDF download Advertisement SubjectsEndothelium/Vascular Type/Nitric OxideMetabolismPulmonary Biology